^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GENOMIC LANDSCAPE OF ENTRECTINIB RESISTANCE FROM CTDNA ANALYSIS IN STARTRK-2
Published date:
09/28/2019
Excerpt:
BRAF V600E and KRAS G12D mutations were detected at progression from a pancreatic cancer patient who had a partial response.
Trial ID:
